Viral Vector Manufacture

30 March -1 April 2020 | Business Design Centre London

 

 

2000+
Attendees
700+
1-2-1 Meetings
300+
Speakers
100+
Exhibitors
12
Streams

 

 

Viral Vector Manufacture

VIRAL VECTOR MANUFACTURE, Tuesday 31 March 2020

CONFERENCE DAY 1 - TUESDAY 31st March 2020

Opening Keynotes Day 1 – CAR-T & Immunotherapy focus

08:45

Welcome – Jessica Robinson, Project Director, Advanced Therapies 2020, Terrapinn

Prasad Adusumilli
09:00

Keynote presentaton: Autologous Mesothelin-targeting CAR-T to tackle solid tumours in the clinic

  • The presentation will highlight results to date of mesothelin-targeted CAR T-cell clinical trial results
  • Advances in preclinical research of CAR T-cell therapy for solid tumors will be presented
  • Novel strategies for overcoming hurdles to solid tumor CAR T-cell therapy will be discussed
Panel discussion
Bradley Campbell
10:00

Importance of patient focus in developing gene therapy for rare diseases

10:20

Morning Coffee Break

Martin Pule
11:20

Keynote presentation: War in the Blood - the latest in the front line of CAR-T clinical research

Mark Sawicki
11:40

Effective Integration Strategies Through a Compliance Unified Ecosystem (CUE)

  • Systems Integration continues to be a major issue in the production and distribution of Advanced Therapies
  • Well-defined strategies for the integration of independent informatics platforms will be critical for future standardization and workflow optimization
  • Cryoport’s Compliance Unified Ecosystem (CUE) is driving standard practices for systems integration in the industry
round tables
12:00

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for you

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for your table number to participate.
1. Raw material supply for the commercial manufacturing of cell and gene therapies
Frank Hecht

Frank Hecht, Vice President Marketing And Sales, CellGenix GmbH

10. Exploring the crossover between human and veterinary applications for stem cells
Joanna Miller

Joanna Miller, Chief Scientific Officer, Cell Therapy Sciences

15. Industry-no profit alliances: how to optimize synergies
Elena Beltrami

Elena Beltrami, Business Development Manager, Fondazione Telethon

17. How companies can interact with the regulator and various pitfalls to be aware of
John Johnston

John Johnston, Clinical Assessor, Medicines & Healthcare Products Regulatory Agency

19. Roundtable available
2. Physiological conditions and analytical and monitoring tools for 3D cell cultivations
Cornelia Kasper

Cornelia Kasper, Professor, Biopharmaceutical Production And Technology, BOKU

3. Ensuring safe delivery to patients and fast time-to-market of advanced therapies - How to address challenges of drug administration, fill & finish, packaging & stability?
Diana Lober

Diana Lober, Product Manager, Schott AG

5. Considerations for manufacture scale-up from academia to commercial manufacturing
Johannes Van Der Loo

Johannes Van Der Loo, Clinical Vector Core Director, The Children's Hospital of Philadelphia

7. Reserved for Fujifilm Diosynth Biotechnology
13:00

Lunch

VIRAL VECTOR MANUFACTURE

Process development

VIRAL VECTOR MANUFACTURE
14:20

Developing robust manufacturing processes for novel gene therapies

Francesca Bellintani
VIRAL VECTOR MANUFACTURE
14:40

Large Scale Production of LV and RV Vectors for T- and CD34+ Cells Transduction

  • Molmed capability for vector production and purification at different scales
  • Challenges for production and purification of LV and RV vectors: from development to GMP
  • Challenges for scaling-up/scaling-out production and purification of LV and RV vectors
Manuel Carrondo
VIRAL VECTOR MANUFACTURE
15:00

Continuous downstream processing, from gene therapy viruses to exosomes

Steven Pincus
VIRAL VECTOR MANUFACTURE
15:20

A look at Fujifilm Diosynth Development of an Advanced Gene Therapy Platform

  • Cell line selection
  • Plasmid offering
  • Analytical Tool Box
Jean-Philippe Combal
VIRAL VECTOR MANUFACTURE
15:40

Collaborative strategy for AAV Manufacturing for Biotech: is In or Out the only model?

Devyn Smith
VIRAL VECTOR MANUFACTURE
16:00

Case study: In-house manufacture vs. outsourcing – why and when?

  • When should you think about in-house manufacture instead of outsourcing?
  • What components do you have to monitor
  • Managing complex supply chain with different suppliers
  • How do you prioritise pushing multiple products
  • When to transition from out to in? if ever?
16:20

Afternoon Break

Leonard Pattenden
VIRAL VECTOR MANUFACTURE
17:00

Lentiviral vector production for advanced therapies

18:00

Close of Conference for the day - Please join us for an evening drinks reception

last published: 05/Mar/20 17:05

VIRAL VECTOR MANUFACTURE, Wednesday 1 April 2020

CONFERENCE DAY 1 - WEDNESDAY 1st April 2020

Opening Keynotes Day 2 — The latest science in gene therapy and gene editing

Federico Mingozzi
09:00

Gene therapy 2.0: New clinical data, therapeutic applications and next generation technologies

  • Latest updates on LUXTURNA studies to treat blindness, haemophilia and rare disease
  • Tackling the challenges of viral gene therapies i.e. immunogenicity
  • Developing the next generation of gene therapies, what does the future hold?
Steve Kanner
09:20

Next-generation gene editing technology for allogeneic immune cell therapeutics

  • Next-generation CRISPR-Cas9 technology
  • Significantly enhanced editing specificity
  • Editing in immune cells for generation of functionally tuned therapeutics
09:40

Repairing the human genome with designed zinc finger editing reagents

  • Overview of Sangamo’s zinc finger protein gene editing technology, including new innovations that facilitate specificity, precision, and gene editing efficiency
  • Will address specific examples of defined therapeutic applications including the generation of reagents suitable for use in tauopathies, Huntington’s disease, and lysosomal storage diseases
Frederic Chereau
10:00

In vivo gene editing paediatric patients with rare diseases

10:20

Networking Refreshments

VIRAL VECTOR MANUFACTURE

Chair: Manuel Carrondo, Professor of Chemical & Biochemical Engineering, FCT-UNL, Vice-President, IBET

Lawrence Thompson
VIRAL VECTOR MANUFACTURE
11:20

Plasmid DNA Control Strategy & AAV Production

  • Specifications, Comparability, Potency assays, Stability, etc.
  • Method & Process Validation
  • Safety Risk vs Business Risk
  • Current Regulatory Guidance
Johannes Van Der Loo
VIRAL VECTOR MANUFACTURE
12:00

Challenges and concepts of designing a new GMP manufacturing facility at an academic centre

  • GMP manufacturing at the Children’s Hospital of Philadelphia
  • Facility design challenges, concepts, and considerations
  • Process of Safety Risk Assessment and FDA interaction
  • Challenges associated with the growing field of gene therapy
Jarema (Jarko) Kochan
VIRAL VECTOR MANUFACTURE
12:40

Assay development for oncolytics

  • Early data
  • Trials and tribulations
  • How to transform data analysis
13:00

Neworking Lunch

VIRAL VECTOR MANUFACTURE

Chair: Manuel Carrondo, Professor of Chemical & Biochemical Engineering, FCT-UNL, Vice-President, IBET

Aisleen Mccoll-Carboni
VIRAL VECTOR MANUFACTURE
14:00

Phase-Appropriate Potency Assays for AAV Gene Therapy Products

Aisleen Mccoll-Carboni, Senior Scientist, Sanofi
Pierre-Albert Colcomb
VIRAL VECTOR MANUFACTURE
14:20

Industrialization of gene therapy manufacturing

Overcoming manufacturing challenges faced by therapy developers- Effectively preparing for later stage trials and commercialization
Christine Le Bec
VIRAL VECTOR MANUFACTURE
14:40

TBC Strategies and Advances in AAV Vector Characterization : Product- Related Impurities

Hartmut Tintrup
VIRAL VECTOR MANUFACTURE
15:00

Enabling the industrialization of cell and gene therapies through process development and platforms for commercial readiness

Jelena Ochs
VIRAL VECTOR MANUFACTURE
15:20

Fully automated cell production for the therapies of the future

Masahiro Kino - Oka
VIRAL VECTOR MANUFACTURE
15:40

Novel concept of “cell manufacturability” and its application to automated cell manufacturing of retina epithelial pigment cells

Christine Le Bec
VIRAL VECTOR MANUFACTURE
15:40

TBC Strategies and Advances in AAV Vector Characterization: Product-Related Impurities

16:00

Networking refreshments

CELL THERAPY & VIRAL VECTOR MANUFACTURE

Chair: Ioannis Papantoniou, Principal Investigator, FORTH (Foundation of Research and Technology); Adjunct Professor, KU Leuven

Panel discussion
VIRAL VECTOR MANUFACTURE
16:30

Panel discussion: moving towards ‘smart’ and ‘flexible’ integrated process pipelines

a. What are the common bioprocess units suitable for all ATMP manufacture – technology and scale perspectives? b..…and what are the specialisations when it comes to different therapy types? i.Technologiesii.Tools iii. Data c. Inherently variable field eliminating sources of systemic uncertainty towards process streamliningd. Whole-process intensification in cell therapy manufacturing: room to improve
18:00

Close of conference

last published: 05/Mar/20 17:05